### ü´Å Pulmonary Medicine: Lung Transplantation in Severe COPD

#### ‚úÖ True Statements
1. **Lung transplantation** in appropriately selected patients with **chronic obstructive pulmonary disease (COPD)** can improve **quality of life** and provides a **median life expectancy of 5.9 years**.
2. Lung transplantation should be considered in patients with COPD who have a **high risk of dying within 2 years** and a **high probability of 90-day postoperative survival**.
3. Referral for lung transplantation evaluation in COPD should take into account **life expectancy**, **quality of life**, and **goals of care**.
4. Referral for lung transplantation evaluation in COPD can be considered when the **BODE index (BMI, airflow obstruction, dyspnea, and exercise capacity) is 5 or 6**.
5. Referral for lung transplantation evaluation in COPD can be considered in the presence of **resting hypoxemia**.
6. Referral for lung transplantation evaluation in COPD can be considered in the presence of **hypercapnia**.
7. Referral for lung transplantation evaluation in COPD can be considered if the **FEV1 is less than 25% of predicted**.
8. Referral for lung transplantation evaluation in COPD can be considered in the presence of **significant exercise limitation** despite **medical therapy**, **smoking cessation**, and **participation in pulmonary rehabilitation**.
9. **Oral glucocorticoids**, such as **prednisone**, should **not** be used for long-term treatment of COPD because of significant adverse effects.
10. In COPD, oral glucocorticoids should be limited to **short courses during acute exacerbations**, when they can improve function, reduce length of stay, and decrease treatment failure.
11. **Lung volume reduction surgery** may improve quality of life, exercise tolerance, and survival in patients with **upper lobe‚Äìpredominant emphysema** and significant exercise limitation.
12. **Lung volume reduction surgery** is contraindicated in patients with COPD who have **non‚Äìupper lobe disease**, **FEV1 less than 20% of predicted**, or **diffusing capacity less than 20% of predicted**, because of high operative mortality.
13. **Roflumilast**, a **selective phosphodiesterase-4 inhibitor**, decreases the frequency of exacerbations in patients with **severe COPD (FEV1 <50% of predicted)** and a **chronic bronchitis phenotype**.
14. Roflumilast is not beneficial in patients with COPD and an **emphysematous subtype**.

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #LungTransplantation #BODEIndex #Glucocorticoids #LungVolumeReduction #Roflumilast #AmbulatoryCare

#### üìö Reference
Global Initiative for Chronic Obstructive Lung Disease. *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease.* 2025 Report. https://goldcopd.org/2025-gold-report/. Accessed May 20, 2025.

#### üÜî Question ID
PMMCQ24060

#### üïí Last Updated
June 2025

---

#### üìñ Related Text
MKSAP 19: Pulmonary Medicine ‚Äî Airways Disease, Chronic Obstructive Pulmonary Disease, Management of COPD, Nonpharmacologic Therapy for COPD, Lung Transplantation

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Lung transplantation** improves **quality of life** in patients with **severe COPD** and is associated with a **median life expectancy of 5.9 years**.
2. Referral for lung transplantation evaluation in COPD should be based on **life expectancy**, **quality of life**, and **patient preferences**.
3. Patients with COPD who are at **high risk of dying within 2 years** and have a **high probability of 90-day postoperative survival** are considered candidates for lung transplantation.
4. Patients with COPD may be referred for lung transplantation evaluation if they have a **BODE index of 5 or 6**.
5. Patients with COPD may be referred for lung transplantation evaluation if they have **resting hypoxemia**.
6. Patients with COPD may be referred for lung transplantation evaluation if they have **hypercapnia**.
7. Patients with COPD may be referred for lung transplantation evaluation if the **FEV1 is less than 25% of predicted**.
8. Patients with COPD may be referred for lung transplantation evaluation if they have **significant exercise limitation** despite **medical therapy**, **smoking cessation**, and **pulmonary rehabilitation**.

#### ‚úÖ True Statements (Consolidated Criteria)
9. Referral for **lung transplantation evaluation** in patients with **chronic obstructive pulmonary disease (COPD)** may be considered if any of the following are present:
   - **BODE index** of 5 or 6  
   - **Resting hypoxemia**  
   - **Hypercapnia**  
   - **FEV1 less than 25% of predicted**  
   - **Significant exercise limitation** despite medical therapy, smoking cessation, and pulmonary rehabilitation

#### üè∑Ô∏è Tags
#PulmonaryMedicine #COPD #LungTransplantation #BODEIndex #AmbulatoryCare
